E
Many Bright Ideas Technologies Inc.
MBGNF
$0.01
$0.000.00%
E
Sell
10/27/2023Downgrade
Many Bright Ideas Technologies Inc. (MBGNF) was downgraded to E+ from D- on 10/27/2023 due to a noticeable decline in the volatility index and total return index.
Many Bright Ideas Technologies Inc. (MBGNF) was downgraded to E+ from D- on 10/27/2023 due to a noticeable decline in the volatility index and total return index.
D
Sell
10/6/2023Upgraded
Many Bright Ideas Technologies Inc. (MBGNF) was upgraded to D- from E- on 10/6/2023 due to an increase in the solvency index. The quick ratio increased from 0.01 to 0.02.
Many Bright Ideas Technologies Inc. (MBGNF) was upgraded to D- from E- on 10/6/2023 due to an increase in the solvency index. The quick ratio increased from 0.01 to 0.02.
E
Sell
3/20/2023Downgrade
Many Bright Ideas Technologies Inc. (MBGNF) was downgraded to E- from D on 3/20/2023 due to a decline in the total return index and solvency index. The quick ratio declined from 0.03 to 0.03.
Many Bright Ideas Technologies Inc. (MBGNF) was downgraded to E- from D on 3/20/2023 due to a decline in the total return index and solvency index. The quick ratio declined from 0.03 to 0.03.
D
Sell
5/31/2022Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 5/31/2022 due to a noticeable increase in the growth index. Operating cash flow increased 205.38% from -$9.3 to $9.8, and EBIT increased 54.71% from -$22.3 to -$10.1.
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 5/31/2022 due to a noticeable increase in the growth index. Operating cash flow increased 205.38% from -$9.3 to $9.8, and EBIT increased 54.71% from -$22.3 to -$10.1.
D
Sell
5/13/2022Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index and total return index.
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index and total return index.
D
Sell
4/22/2022Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 4/22/2022 due to a large increase in the growth index. Earnings per share increased from -$0.0013 to -$0.0006, and operating cash flow increased 8.82% from -$10.2 to -$9.3.
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 4/22/2022 due to a large increase in the growth index. Earnings per share increased from -$0.0013 to -$0.0006, and operating cash flow increased 8.82% from -$10.2 to -$9.3.
D
Sell
4/20/2022Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 4/20/2022 due to a major decline in the growth index. Earnings per share declined from -$0.0007 to -$0.0013, and EBIT declined 66.67% from -$9.3 to -$15.5.
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 4/20/2022 due to a major decline in the growth index. Earnings per share declined from -$0.0007 to -$0.0013, and EBIT declined 66.67% from -$9.3 to -$15.5.
D
Sell
11/23/2021Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
7/31/2020Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from E+ on 7/31/2020 due to a major increase in the growth index and volatility index. Operating cash flow increased 109.43% from -$10.6 to $1.
Med BioGene Inc. (MBGNF) was upgraded to D from E+ on 7/31/2020 due to a major increase in the growth index and volatility index. Operating cash flow increased 109.43% from -$10.6 to $1.
E
Sell
5/29/2020Downgrade
Med BioGene Inc. (MBGNF) was downgraded to E+ from D on 5/29/2020 due to a large decline in the growth index and volatility index. Earnings per share declined from -$0.0002 to -$0.0012, and EBIT declined 453.57% from -$2.8 to -$15.5.
Med BioGene Inc. (MBGNF) was downgraded to E+ from D on 5/29/2020 due to a large decline in the growth index and volatility index. Earnings per share declined from -$0.0002 to -$0.0012, and EBIT declined 453.57% from -$2.8 to -$15.5.
D
Sell
5/19/2020Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 5/19/2020 due to an increase in the volatility index, growth index and total return index.
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 5/19/2020 due to an increase in the volatility index, growth index and total return index.
D
Sell
5/1/2020Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index and total return index.
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index and total return index.
D
Sell
4/30/2020Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D from D+ on 4/30/2020 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 0.48 to 0.22.
Med BioGene Inc. (MBGNF) was downgraded to D from D+ on 4/30/2020 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 0.48 to 0.22.
D
Sell
7/9/2019Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D+ from D on 7/9/2019 due to an increase in the volatility index and total return index.
Med BioGene Inc. (MBGNF) was upgraded to D+ from D on 7/9/2019 due to an increase in the volatility index and total return index.
D
Sell
5/28/2019Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from E+ on 5/28/2019 due to a significant increase in the efficiency index, growth index and total return index. Operating cash flow increased 117.39% from -$6.9 to $1.2.
Med BioGene Inc. (MBGNF) was upgraded to D from E+ on 5/28/2019 due to a significant increase in the efficiency index, growth index and total return index. Operating cash flow increased 117.39% from -$6.9 to $1.2.
E
Sell
4/18/2019Downgrade
Med BioGene Inc. (MBGNF) was downgraded to E+ from D on 4/18/2019 due to a significant decline in the efficiency index, growth index and total return index. Earnings per share declined from -$0.0009 to -$0.0048, operating cash flow declined 309.09% from $3.3 to -$6.9, and EBIT declined 131.51% from -$7.3 to -$16.9.
Med BioGene Inc. (MBGNF) was downgraded to E+ from D on 4/18/2019 due to a significant decline in the efficiency index, growth index and total return index. Earnings per share declined from -$0.0009 to -$0.0048, operating cash flow declined 309.09% from $3.3 to -$6.9, and EBIT declined 131.51% from -$7.3 to -$16.9.
D
Sell
6/5/2018Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from E+ on 6/5/2018 due to a significant increase in the efficiency index, growth index and total return index. EBIT increased 67.91% from -$21.5 to -$6.9, earnings per share increased from -$0.0033 to -$0.0015, and net income increased 53.68% from -$28.5 to -$13.2.
Med BioGene Inc. (MBGNF) was upgraded to D from E+ on 6/5/2018 due to a significant increase in the efficiency index, growth index and total return index. EBIT increased 67.91% from -$21.5 to -$6.9, earnings per share increased from -$0.0033 to -$0.0015, and net income increased 53.68% from -$28.5 to -$13.2.
E
Sell
5/2/2018Downgrade
Med BioGene Inc. (MBGNF) was downgraded to E+ from D on 5/2/2018 due to a significant decline in the efficiency index, growth index and volatility index. EBIT declined 216.98% from -$10.6 to -$33.6, net income declined 156.76% from -$11.1 to -$28.5, and earnings per share declined from -$0.0013 to -$0.0033.
Med BioGene Inc. (MBGNF) was downgraded to E+ from D on 5/2/2018 due to a significant decline in the efficiency index, growth index and volatility index. EBIT declined 216.98% from -$10.6 to -$33.6, net income declined 156.76% from -$11.1 to -$28.5, and earnings per share declined from -$0.0013 to -$0.0033.
D
Sell
1/3/2018Downgrade
Med BioGene Inc. (MBGND) was downgraded to D from D+ on 1/3/2018 due to a decline in the total return index and volatility index.
Med BioGene Inc. (MBGND) was downgraded to D from D+ on 1/3/2018 due to a decline in the total return index and volatility index.
D
Sell
12/19/2017Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D+ from D on 12/19/2017 due to an increase in the volatility index.
Med BioGene Inc. (MBGNF) was upgraded to D+ from D on 12/19/2017 due to an increase in the volatility index.
D
Sell
11/24/2017Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 11/24/2017 due to a significant increase in the efficiency index and total return index. Net income increased 52.77% from -$23.5 to -$11.1.
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 11/24/2017 due to a significant increase in the efficiency index and total return index. Net income increased 52.77% from -$23.5 to -$11.1.
D
Sell
11/17/2017Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 11/17/2017 due to a decline in the volatility index.
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 11/17/2017 due to a decline in the volatility index.
D
Sell
9/1/2017Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 9/1/2017 due to an increase in the growth index, volatility index and total return index. EBIT increased 91.42% from -$271.6 to -$23.3, earnings per share increased from -$0.0032 to -$0.0003, and operating cash flow increased 50.81% from -$24.8 to -$12.2.
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 9/1/2017 due to an increase in the growth index, volatility index and total return index. EBIT increased 91.42% from -$271.6 to -$23.3, earnings per share increased from -$0.0032 to -$0.0003, and operating cash flow increased 50.81% from -$24.8 to -$12.2.
D
Sell
6/1/2017Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 6/1/2017 due to a large decline in the growth index, valuation index and solvency index. EBIT declined 2,219.33% from -$11.9 to -$276, earnings per share declined from $0.0003 to -$0.0032, and operating cash flow declined 171.06% from $34.9 to -$24.8.
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 6/1/2017 due to a large decline in the growth index, valuation index and solvency index. EBIT declined 2,219.33% from -$11.9 to -$276, earnings per share declined from $0.0003 to -$0.0032, and operating cash flow declined 171.06% from $34.9 to -$24.8.
D
Sell
5/26/2017Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 5/26/2017 due to an increase in the total return index and volatility index.
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 5/26/2017 due to an increase in the total return index and volatility index.
D
Sell
5/10/2017Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 5/10/2017 due to a large decline in the efficiency index and volatility index.
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 5/10/2017 due to a large decline in the efficiency index and volatility index.
D
Sell
3/21/2017Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 3/21/2017 due to an increase in the volatility index.
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 3/21/2017 due to an increase in the volatility index.
D
Sell
2/9/2017Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 2/9/2017 due to a decline in the volatility index.
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 2/9/2017 due to a decline in the volatility index.
D
Sell
1/25/2017Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 1/25/2017 due to an increase in the volatility index.
Med BioGene Inc. (MBGNF) was upgraded to D from D- on 1/25/2017 due to an increase in the volatility index.
D
Sell
1/10/2017Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 1/10/2017 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.53 to 0.25.
Med BioGene Inc. (MBGNF) was downgraded to D- from D on 1/10/2017 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.53 to 0.25.
D
Sell
8/26/2016Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D from D+ on 8/26/2016 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from $0.0003 to -$0.0003, net income declined 172.85% from $30.2 to -$22, and EBIT declined 92.98% from -$11.4 to -$22.
Med BioGene Inc. (MBGNF) was downgraded to D from D+ on 8/26/2016 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from $0.0003 to -$0.0003, net income declined 172.85% from $30.2 to -$22, and EBIT declined 92.98% from -$11.4 to -$22.
D
Sell
8/11/2016Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D+ from C- on 8/11/2016 due to a major decline in the total return index and volatility index.
Med BioGene Inc. (MBGNF) was downgraded to D+ from C- on 8/11/2016 due to a major decline in the total return index and volatility index.
C
Hold
5/31/2016Upgraded
Med BioGene Inc. (MBGNF) was upgraded to C- from D on 5/31/2016 due to a significant increase in the efficiency index and growth index. Net income increased 119.09% from -$158.2 to $30.2, earnings per share increased from -$0.0018 to $0.0003, and EBIT increased 88.74% from -$155.4 to -$17.5.
Med BioGene Inc. (MBGNF) was upgraded to C- from D on 5/31/2016 due to a significant increase in the efficiency index and growth index. Net income increased 119.09% from -$158.2 to $30.2, earnings per share increased from -$0.0018 to $0.0003, and EBIT increased 88.74% from -$155.4 to -$17.5.
D
Sell
4/22/2016Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D from C- on 4/22/2016 due to a significant decline in the efficiency index, solvency index and total return index. Net income declined 492.51% from -$26.7 to -$158.2, total capital declined 242.05% from -$17.6 to -$60.2, and the quick ratio declined from 0.64 to 0.31.
Med BioGene Inc. (MBGNF) was downgraded to D from C- on 4/22/2016 due to a significant decline in the efficiency index, solvency index and total return index. Net income declined 492.51% from -$26.7 to -$158.2, total capital declined 242.05% from -$17.6 to -$60.2, and the quick ratio declined from 0.64 to 0.31.
C
Hold
3/28/2016Upgraded
Med BioGene Inc. (MBGNF) was upgraded to C- from D+ on 3/28/2016 due to a noticeable increase in the total return index and volatility index.
Med BioGene Inc. (MBGNF) was upgraded to C- from D+ on 3/28/2016 due to a noticeable increase in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D+ from C- on 3/11/2016 due to a major decline in the volatility index.
Med BioGene Inc. (MBGNF) was downgraded to D+ from C- on 3/11/2016 due to a major decline in the volatility index.
C
Hold
3/2/2016Downgrade
Med BioGene Inc. (MBGNF) was downgraded to C- from C on 3/2/2016 due to a decline in the volatility index and total return index.
Med BioGene Inc. (MBGNF) was downgraded to C- from C on 3/2/2016 due to a decline in the volatility index and total return index.
C
Hold
2/16/2016Upgraded
Med BioGene Inc. (MBGNF) was upgraded to C from C- on 2/16/2016 due to an increase in the volatility index.
Med BioGene Inc. (MBGNF) was upgraded to C from C- on 2/16/2016 due to an increase in the volatility index.
C
Hold
2/1/2016Downgrade
Med BioGene Inc. (MBGNF) was downgraded to C- from C on 2/1/2016 due to a noticeable decline in the volatility index and valuation index.
Med BioGene Inc. (MBGNF) was downgraded to C- from C on 2/1/2016 due to a noticeable decline in the volatility index and valuation index.
C
Hold
1/7/2016Upgraded
Med BioGene Inc. (MBGNF) was upgraded to C from D+ on 1/7/2016 due to an increase in the growth index.
Med BioGene Inc. (MBGNF) was upgraded to C from D+ on 1/7/2016 due to an increase in the growth index.
D
Sell
11/27/2015Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D+ from D on 11/27/2015 due to a significant increase in the efficiency index and valuation index.
Med BioGene Inc. (MBGNF) was upgraded to D+ from D on 11/27/2015 due to a significant increase in the efficiency index and valuation index.
D
Sell
7/13/2015Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D from D+ on 7/13/2015 due to a decline in the total return index and volatility index.
Med BioGene Inc. (MBGNF) was downgraded to D from D+ on 7/13/2015 due to a decline in the total return index and volatility index.
D
Sell
6/3/2015Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D+ from C on 6/3/2015 due to a significant decline in the efficiency index and valuation index. Total capital declined 224.8% from -$38.3 to $47.8, and net income declined 56.93% from -$150.9 to -$65.
Med BioGene Inc. (MBGNF) was downgraded to D+ from C on 6/3/2015 due to a significant decline in the efficiency index and valuation index. Total capital declined 224.8% from -$38.3 to $47.8, and net income declined 56.93% from -$150.9 to -$65.
C
Hold
5/1/2015Upgraded
Med BioGene Inc. (MBGNF) was upgraded to C from D on 5/1/2015 due to a significant increase in the efficiency index and valuation index. Net income increased 1,310.28% from -$10.7 to -$150.9.
Med BioGene Inc. (MBGNF) was upgraded to C from D on 5/1/2015 due to a significant increase in the efficiency index and valuation index. Net income increased 1,310.28% from -$10.7 to -$150.9.
D
Sell
12/3/2014Downgrade
Med BioGene Inc. (MBGNF) was downgraded to D from D+ on 12/3/2014 due to a noticeable decline in the efficiency index and valuation index. Total capital declined 719.13% from -$18.3 to $113.3, and net income declined 81.26% from -$57.1 to -$10.7.
Med BioGene Inc. (MBGNF) was downgraded to D from D+ on 12/3/2014 due to a noticeable decline in the efficiency index and valuation index. Total capital declined 719.13% from -$18.3 to $113.3, and net income declined 81.26% from -$57.1 to -$10.7.
D
Sell
9/4/2014Upgraded
Med BioGene Inc. (MBGNF) was upgraded to D+ from D on 9/4/2014 due to an increase in the valuation index, efficiency index and growth index.
Med BioGene Inc. (MBGNF) was upgraded to D+ from D on 9/4/2014 due to an increase in the valuation index, efficiency index and growth index.
OTC PK
12/02/2024 10:04AM Eastern
Quotes delayed
